We aimed to measure sensitivity, specificity, and to determine the cut-off value (COV) ratio of neutrophil-to-lymphocyte (NLR) in patients with active systemic lupus erythematosus (SLE).
Methods
A cross sectional study was conducted using the retrospective data from Hasan Sadikin Lupus Registry (HSLR). The inclusion criteria were SLE patients aged 18 years or older who had documented data of neutrophil, lymphocyte, and SLE disease activity index (SLEDAI). Patients with infections, malignancies, and other inflammatory diseases recorded in registry were excluded. SLEDAI with a score of ≤ 4 is considered inactive and score of > 4 is considered active. The neutrophil-to-lymphocyte ratio was calculated by dividing the absolute number of neutrophils by the absoulte number of lymphocytes. Receiver Operating Characteristic (ROC) curve was used to analyze and determine optimal COV of NLR.
Results
The total sample in this study were 112 subjects with a dominant of female (95.54%) and the mean age of 34.45 ± 9.40 years. The median of SLEDAI was 4.5 with a range from 0 to 16, while the median of NLR was 2.68 with a range of 0.59 to 19.02. The ROC analysis showed the optimal cut-off in this study was 2.94 with sensitivity and specificity as high as 60.71% and 76.79%, respectively.
Conclusion
Neutrophil-to-lymphocyte ratio with cut off value of 2.94 can be used to determine active disease of systemic lupus eythematousus.
AshanyDCrowM.Experimental approaches to the study of autoimmune rheumatic diseases. In: ZabriskieJB (eds.) Essential clinical immunology.
New York:
Cambridge University Press, 2009, pp. 182–187.
2.
KumarVAbbasAKAsterJC.Disease of the immune system. In: Robbins basic pathology. 9th ed.
Philadelphia:
Elsevier Saunders, 2013, pp. 125–131.
3.
HamijoyoLCandrianitaSRahmadiAR, et al.
The clinical characteristics of systemic lupus erythematosus patients in Indonesia: a cohort registry from an Indonesia-based tertiary referral hospital. Lupus2019;
28: 1604–1609.
4.
HahnBH.Systemic lupus erythematosus. In: KasperDLHauserSLJamesonJLFauciASLongoDLLoscalzoJ (eds) Harrison’s principles of internal medicine. 19th ed.
New York:
McGraw-Hill Education, 2015, pp. 2124–2136.
5.
Vasquez-CanizaresNWaheziDPuttermanC.Diagnostic and prognostic tests in systemic lupus erythematosus. Best Pract Res Clin Rheumatol2017;
31: 351–363.
6.
Yang XF, Ding FM, Ye YC and Zhang SY. Relationship between neutrophil-to-lymphocyte ratio and pulse wave velocity in young patients with systemic lupus erythematosus. Chin Med J (Engl) 2018; 131: 10–15.
7.
QinBMaNTangQ, et al.
Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were useful markers in assessment of inflammatory response and disease activity in SLE patients. Mod Rheumatol2016;
26: 372–376.
8.
Wu Y, Chen Y, Yang X, Chen L and Yang Y. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were associated with disease activity in patients with systemic lupus erythematosus. Int Immunopharmacol 2016; 36: 94–99.
9.
YuHJiangLYaoL, et al.
Predictive value of the neutrophil-to-lymphocyte ratio and hemoglobin in systemic lupus erythematosus. Exp Ther Med2018;
16: 1547–1553.
10.
YuJZengTWuY, et al.
Neutrophil-to-C3 ratio and neutrophil-to-lymphocyte ratio were associated with disease activity in patients with systemic lupus erythematosus. J Clin Lab Anal2019;
33: e22633.
11.
YangZZhangZLinF, et al.
Comparisons of neutrophil-, monocyte-, eosinophil-, and basophil-lymphocyte ratios among various systemic autoimmune rheumatic diseases. Apmis2017;
125: 863–871.
12.
CelikbilekMDoganSOzbakirO, et al.
Neutrophil-lymphocyte ratio as a predictor of disease severity in ulcerative colitis. J Clin Lab Anal2013;
27: 72–76.
13.
AfsarB.The relationship between neutrophil lymphocyte ratio with urinary protein and albumin excretion in newly diagnosed patients with type 2 diabetes. Am J Med Sci2014;
347: 217–220.
14.
MotomuraTShirabeKManoY, et al.
Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol2013;
58: 58–64.
15.
KimHAJungJYSuhCH.Usefulness of neutrophil-to-lymphocyte ratio as a biomarker for diagnosing infections in patients with systemic lupus erythematosus. Clin Rheumatol2017;
36: 2479–2485.
16.
Broca-GarciaBESaavedraMAMartinez-BencomoMA, et al.
Utility of neutrophil-to-lymphocyte ratio plus C-reactive protein for infection in systemic lupus erythematosus. Lupus2019;
28: 217–222.
17.
UthamalingamSPatvardhanEASubramanianS, et al.
Utility of the neutrophil to lymphocyte ratio in predicting long-term outcomes in acute decompensated heart failure. Am J Cardiol2011;
107: 433–438.
18.
FuHQinBHuZ, et al.
Neutrophil-and platelet-to-lymphocyte ratios are correlated with disease activity in rheumatoid arthritis. Clin Lab2015;
61: 269–273.
19.
Soliman WM, Sherif NM, Ghanima IM and EL-Badawy MA. Neutrophil to lymphocyte and platelet to lymphocyte ratios in systemic lupus erythematosus: relation with disease activity and lupus nephritis. Rheumatol Clin 2020; 16: 255–261.
20.
Li L, Xia Y, Chen C, Cheng P and Peng C. Neutrophil-lymphocyte ratio in systemic lupus erythematosus disease: a retrospective study. Int J Clin Exp Med 2015; 8: 11026–11031.
21.
Ayna AB, Ermurat S, Coskun BN, Harman H and Pehlivan Y. Neutrophil to lymphocyte ratio and mean platelet volume as inflammatory indicators in systemic lupus erythematosus nephritis. Arch Rheumatol 2017; 32: 21–25.
22.
GergianakiIBertsiasG.Systemic lupus erythematosus in primary care: an update and practical messages for the general practitioner. Front Med2018;
5: 1–12.
23.
PeschkenCAWangYAbrahamowiczM, et al.; on behalf of CaNIOS 1000 Faces Investigators.
Persistent disease activity remains a burden for patients with systemic lupus erythematosus. J Rheumatol2019;
46: 166–175.
24.
Amissah-ArthurMBGordonC.Contemporary treatment of systemic lupus erythematosus: an update for clinicians. Ther Adv Chronic Dis2010;
1: 163–175.
25.
PetriMOrbaiAMAlarcõnGS, et al.
Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum2012;
64: 2677–2686.
26.
HochbergMC.Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997;
40: 1725.
27.
YeeC-SFarewellVTIsenbergDA, et al.
The use of systemic lupus erythematosus disease activity index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford)2011;
50: 982–988.
28.
Kandane-RathnayakeRGolderVLouthrenooW, et al.
Development of the Asia Pacific lupus collaboration cohort. Int J Rheum Dis2019;
22: 425–433.
29.
Hajian-TilakiK.Sample size estimation in diagnostic test studies of biomedical informatics. J Biomed Inform2014;
48: 193–204.
30.
MescherA.The immune system and lymphoid organs. In: Junqueira basic histology text and atlas. 14th ed.
New York:
McGraw-Hill Education, 2016, pp. 262–288.
31.
FayyazAIgoeAKurienBT, et al.
Haematological manifestations of lupus. Lupus Sci Med2015;
2: 1–18.
32.
TrevethanR.Sensitivity, specificity, and predictive values: foundations, pliabilities, and pitfalls in research and practice. Front Public Health2017;
5: 307.
33.
Kan HJ, Song X, Johnson BH, Bechtel B, O’Sullivan D and Molta CT. Healthcare utilization and costs of systemic lupus erythematosus in medicaid. BioMed Res Int 2013; 2013: 1–8.
34.
PopaRLautaruLALucretiuR, et al.
Therapy side effects in systemic lupus erythematosus. Curr Health Sci J2018;
44: 316–321.
35.
MercanRBitikBTufanA, et al.
The association between neutrophil/lymphocyte ratio and disease activity in rheumatoid arthritis and ankylosing spondylitis. J Clin Lab Anal2016;
30: 597–601.
36.
Chandrashekara S, Mukhtar Ahmad M, Renuka P, Anupama KR and Renuka K. Characterization of neutrophil-to-lymphocyte ratio as a measure of inflammation in rheumatoid arthritis. Int J Rheum Dis 2017; 20: 1457–1467.
